MDX 1303

Drug Profile

MDX 1303

Alternative Names: Anthrax anti-toxin monoclonal antibody - PharmAthene/Medarex/Bristol-Myers-Squibb; Anti-anthrax monoclonal antibody - PharmAthene/Medarex/Bristol-Myers-Squibb; MAb-1303; MDX-1303; Valortim

Latest Information Update: 05 Jun 2014

Price : $50

At a glance

  • Originator Medarex
  • Developer Bristol-Myers Squibb; Medarex; PharmAthene
  • Class Antibacterials; Monoclonal antibodies
  • Mechanism of Action Anthrax toxin inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anthrax
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Anthrax
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Anthrax

Most Recent Events

  • 29 May 2014 Phase I development is ongoing in USA
  • 16 Dec 2013 MDX 1303 (Valortim®) is still in phase I development for Anthrax (prevention and treatment)
  • 06 Dec 2011 Immunogenicity, pharmacokinetics and adverse events data from a phase I trial in Anthrax (healthy volunteers) released by PharmAthene
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top